GLP-1 drugs and weight loss: separating the hype from the data

What did @marilyngalindomd actually say?

Dr. Galindo laid out a pricing breakdown for Fundayo, an oral GLP-1 medication. She said insured patients pay "about $25 per month," uninsured patients pay "anywhere from $1.49 for the starter doses all the way up to $3.49 per month," and Medicare patients will pay "about $50" starting in July. She also compared it favorably to injectable GLP-1s, which she said "start around $2.49 to $500 a month."

The obvious problem here is the numbers. Those price figures, as stated, are almost certainly missing zeroes. Context makes it clear she meant $149 to $349 per month for uninsured patients, and $249 to $500 for injectables. The transcript as delivered is garbled, but the intent is readable. That said, a physician making pricing claims on a platform with over 10,000 views should be precise, because patients will screenshot these numbers and show up at pharmacies expecting to pay a dollar forty-nine.

Does the science back this up?

The affordability argument for oral GLP-1 options versus brand-name injectables is generally supported by real-world pricing data, but the specific numbers need scrutiny. Assuming the corrected figures are what she meant, they are in the right ballpark for current market conditions, though they vary significantly by pharmacy and program.

Oral semaglutide (Rybelsus) has a list price around $900-$1,000 per month without insurance, so if Fundayo is a compounded or alternative oral formulation priced at $149-$349, that would represent meaningful savings. However, compounded GLP-1 oral formulations have not been shown in peer-reviewed trials to be bioequivalent to brand-name products. The FDA has repeatedly warned that compounded drugs are not FDA-approved and carry unknown efficacy and safety profiles. A 2023 FDA advisory note specifically flagged compounded semaglutide products as a concern given the shortage period. Comparing cost without acknowledging the efficacy uncertainty is an incomplete picture.

The Medicare pricing claim around July is plausible given the Inflation Reduction Act's drug negotiation provisions, but the specifics for GLP-1s under Medicare Part D are still being finalized and vary by plan.

What did they get wrong (or right)?

Let's give credit where it is due. The core argument, that oral GLP-1 options are often cheaper out-of-pocket than brand-name injectables like Ozempic or Wegovy, is largely accurate. Wegovy list price sits around $1,300-$1,400 per month without coverage, and even with manufacturer coupons many patients pay $500 or more. If Fundayo delivers at $149-$349, the affordability gap is real.

What she got wrong, or at least omitted, is the efficacy question. She says some patients get "a good response early on," which is true of all GLP-1s, but she implies Fundayo is a direct substitute for injectables without noting that oral bioavailability of semaglutide is substantially lower than subcutaneous delivery. Data from the PIONEER trials (Aroda et al., 2019, Lancet) showed oral semaglutide 14mg produced weight loss, but the effect size was generally smaller than injectable formulations at comparable doses. If Fundayo is a compounded oral product, there is no trial data at all to cite. That gap matters clinically and she did not address it.

The transcript's pricing errors, whether a recording issue or a slip of the tongue, are a problem that should have been caught before posting.

What should you actually know?

If you are considering an oral GLP-1 medication based partly on cost, here is what the evidence actually supports. First, FDA-approved oral semaglutide (Rybelsus) is a legitimate option with clinical trial backing, though it was originally approved for type 2 diabetes, not weight loss specifically. Second, compounded oral GLP-1 products exist in a regulatory gray zone. The FDA does not review them for safety or efficacy before they reach patients, which is a meaningful risk, not a technicality.

Third, the Medicare pricing landscape for GLP-1s is genuinely evolving. The Inflation Reduction Act created a framework for Medicare drug price negotiation, and several Part D plans have begun covering anti-obesity medications more broadly, but the $50 figure cited here is not universally confirmed for this drug specifically. Patients should call their plan directly before assuming any out-of-pocket figure.

Finally, insurance coverage for anti-obesity medications remains inconsistent. A 2022 analysis by Volk et al. in Obesity found that fewer than 40% of commercial plans covered weight loss medications at all, which is consistent with Dr. Galindo's point that "most people don't have insurance coverage." That part, at least, tracks with the data.